SCIENCEDOMAIN *international*
www.sciencedomain.org

SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	British Journal of Pharmaceutical Research
Manuscript Number:	2013_BJPR_3923
Title of the Manuscript:	**Formulation And Evaluation Of Carbamazepine 200 Controlled Release Tablets Using Different Methocel Grades**

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
Compulsory revision comments 1. Abstract: The text is completely the same as in the previous version. It should be revised; author's comments and conclusions should be added. 2. The titles above certain tables are still missing (Pg. 6). 3. The term *geometrically mixed* should be changed with the text that the authors already proposed. 4. Additional explanation related to dissolution testing time and adequate conclusion which correlates the testing product and Tegretol CR should be added in the part 2.3. 5. Based on the obtained results the influence of solubilizer present in the medium of carbamazepine dissolution rate is evident. An adequate explanation related to this topic is still missing. 6. Table 6-Still it is not clearly indicated that f2 factors were calculated by comparing the selected formulation and the reference product, Tegretol CR 200 mg tbs. **Minor revision comments** 1. A few tables were reorganized, but some should be corrected. Table 2.: Formulation Nº should be written instead of *Tablets prepared by*. The average weight: 20 tablets should be tested. Tables 3 and 4-the title should be: % of dissolved CBZ instead of *% of CBZ dissolved from its CR tablets made with*. Table 5: the title should be above the Table. Table 6: buffer 1.2 instead of 2.0. Table 7: from the title it can not be concluded to which formulation the obtained results are related; n=3 unacceptable! Sampling point instead of *sampling location*. Table 8: % of dissolved CBZ instead of *Percent of carbamazepine dissolved from its tablets from different location of scaled up production batch made with.* 2. What does the term *dissolution value* mean? 3. n value can not be the same for different tests; is should be corrected in each table based on compendial requirements. 4. According to USP dissolution test is performed on 6 tablets, but dissolution profiles should be compared based on the results obtained from 12 tablets. **Other comments:** 1. Implemented *amendments* are unnecessary and should be removed. 2. The full text should be checked in order to correct typing errors.	

Reviewer Details:

Name:	**Irena Homšek**
Department, University & Country	**Galenika ad, Batajnički drum bb, 11080 Belgrade, Serbia**